These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 606765)
41. Serological response to an adsorbed killed trivalent influenza vaccine (including A/New Jersey 8/76 antigen). Sarateanu D; Ehrengut W; Pressler K Dev Biol Stand; 1977 Jun 1-3; 39():235-8. PubMed ID: 604102 [TBL] [Abstract][Full Text] [Related]
42. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming? Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948 [TBL] [Abstract][Full Text] [Related]
43. Immune response to influenza vaccine in hemodialysis patients with chronic renal failure. Mastalerz-Migas A; Steciwko A; Brydak LB Adv Exp Med Biol; 2013; 756():285-90. PubMed ID: 22836646 [TBL] [Abstract][Full Text] [Related]
44. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine. Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378 [TBL] [Abstract][Full Text] [Related]
45. [Comparison between killed subunit influenza vaccines and whole virion preparations: study of reactions and protective efficacy in children and adults]. Profeta ML; Bigatello A; Vacchini V; Bramati L; Ferrante P Boll Ist Sieroter Milan; 1980 Jan; 58(6):457-74. PubMed ID: 6778485 [TBL] [Abstract][Full Text] [Related]
46. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Hehme N; Engelmann H; Künzel W; Neumeier E; Sänger R Med Microbiol Immunol; 2002 Dec; 191(3-4):203-8. PubMed ID: 12458361 [TBL] [Abstract][Full Text] [Related]
47. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season. Petrie JG; Ohmit SE; Truscon R; Johnson E; Braun TM; Levine MZ; Eichelberger MC; Monto AS J Infect Dis; 2016 Oct; 214(8):1142-9. PubMed ID: 27095420 [TBL] [Abstract][Full Text] [Related]
49. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy. Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995 [TBL] [Abstract][Full Text] [Related]
50. Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. Ogra PL; Chow T; Beutner KR; Rubi E; Strussenberg J; DeMello S; Rizzone C J Infect Dis; 1977 Apr; 135(4):499-506. PubMed ID: 856917 [TBL] [Abstract][Full Text] [Related]
51. Small-scale field trial with neuraminidase vaccine. Vonka V; Závadová H; Brůj J; Skocil V; Janout V; Uvizl M; Kotíková J Dev Biol Stand; 1977 Jun 1-3; 39():337-9. PubMed ID: 342313 [TBL] [Abstract][Full Text] [Related]
52. Temperature-sensitive mutants of influenza A virus: response of children to the influenza A/Hong Kong/68-ts-1(E) (H3N2) and influenza A/Udorn/72-ts-1(E) (H3N2) candidate vaccine viruses and significance of immunity to neuraminidase antigen. Kim HW; Arrobio JO; Brandt CD; Parrott RH; Murphy BR; Richman DD; Chanock RM Pediatr Res; 1976 Apr; 10(4):238-42. PubMed ID: 1272630 [TBL] [Abstract][Full Text] [Related]
53. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine. Vesikari T; Forstén A; Arora A; Tsai T; Clemens R Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244 [TBL] [Abstract][Full Text] [Related]
54. Antibody formation after vaccination with adsorbed and non-adsorbed A/New Jersey/8/76 influenza vaccines. Schenk KD; Pressler K; Sarateanu DE; Peukert M; Ehrengut W; Schnitker J Pharmatherapeutica; 1982; 3(3):201-8. PubMed ID: 7134228 [TBL] [Abstract][Full Text] [Related]
56. A controlled double-blind comparison of reactogenicity, immunogenicity, and protective efficacy of whole-virus and split-product influenza vaccines in children. Gross PA; Ennis FA; Gaerlan PF; Denson LJ; Denning CR; Schiffman D J Infect Dis; 1977 Nov; 136(5):623-32. PubMed ID: 335000 [TBL] [Abstract][Full Text] [Related]
57. IgM and IgG antibody responses after immunization of children with inactivated monovalent (A/New Jersey/76) and bivalent (A/New Jersey/76-A/Victoria/75) influenza virus vaccines. Boyer KM; Cherry JD; Welliver RC; Dudley JP; Deseda-Tous J; Zahradnik JM; Krause PJ; Spencer MJ; Bryson YJ; Garakian AJ J Infect Dis; 1977 Dec; 136 Suppl():S665-71. PubMed ID: 342632 [TBL] [Abstract][Full Text] [Related]
58. [Formation and protective functions of antibodies to neuraminidase of the influenza A virus]. Naĭkhin AN; Tsaritsyna IM; Oleĭnikova EV; Ismagulov AT; Reznik VI Vopr Virusol; 1985; 30(1):35-9. PubMed ID: 3993000 [TBL] [Abstract][Full Text] [Related]
59. [Rescue of H3N2 subtype swine influenza virus and substitution of hemagglutinin, neuraminidase]. Du J; Liu M; Liu C; Yang T; Li H Wei Sheng Wu Xue Bao; 2009 Jun; 49(6):813-9. PubMed ID: 19673419 [TBL] [Abstract][Full Text] [Related]
60. Human responses to purified surface antigen invluenza vaccine (Fluvirin). Stones PB; Furminger IG; Kerr J Dev Biol Stand; 1977 Jun 1-3; 39():239-42. PubMed ID: 604103 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]